A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.

Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM.

Institute of Psychology, 
Johann Wolfgang Goethe University, 
Frankfurt/Main, Germany.
Neuropsychobiology 1997;36(2):73-82


Two doses of idebenone were studied in a prospective, randomized, double-blind, placebo-controlled multicentre study in patients suffering from dementia of the Alzheimer type (DAT) of mild to moderate degree. Diagnosis was based on DSM-III-R (primary degenerative dementia) and NINCDS-ADRDA criteria (probable Alzheimer's disease). A total of 300 patients were randomized to either placebo, idebenone 30 mg t.i.d. or 90 mg t.i.d. (n = 100, each) and treated for 6 months. The primary outcome measure was the total score of the Alzheimer's Disease Assessment Scale (ADAS-Total) at month 6. Secondary outcome measures were the ADAS cognitive (ADAS-Cog) and noncognitive scores (ADAS-Noncog), the clinical global response (CGI-Improvement), the MMSE, the Digit Symbol Substitution test (DSS) and several scales for the assessment of daily activities (the self- and observer-rating scales NAA and NAB of the Nuremberg Age Inventory NAI and Greene's Assessment). Safety parameters were adverse events, vital signs, ECG and clinical laboratory parameters. Clinical and psychometric evaluations were performed at baseline, and after 1, 3 and 6 months of treatment. After month 6 idebenone 90 mg t.i.d. showed statistically significant improvement in the primary efficacy variable ADAS-Total and in ADAS-Cog. An analysis of therapy responders performed for 3 outcome measures (CGI-global improvement, ADAS-Cog, ADAS-Noncog), selected to represent different domains of assessment, revealed significant superiority of idebenone 90 mg t.i.d. with respect to placebo in each of the 3 variables and in the concordance of responses across the 3 measures. Exploratory results for a subgroup of patients (ADAS-Total > or = 20) showed dose-related superiority of idebenone additionally on ADAS-Noncog and the CGI-Improvement scale. Safety results were inconspicuous for all assessments. The study results demonstrate the efficacy and safety of idebenone in the treatment of DAT patients.

   Home | Order

Idebenone - the ultimate anti-aging drug.  (article)
Alzheimer's disease
Idebenone  in the treatment of Alzheimer's disease
Idebenone  efficacy of idebenone in the treatment of Alzheimer's disease
Idebenone  Nerve Growth Factor synthesis stimulators in Alzheimer's disease
Idebenone  in the treatment of dementia of the Alzheimer type
Idebenone  cognitive enhancement therapy for Alzheimer's disease

Friedreich's ataxia.
Idebenone  and reduced cardiac hypertrophy in Friedreich's ataxia.
enone  causes improvement in mitochondrial cardiomyopathy
Idebenone  cerebellar improvement in Friedreich's ataxia after 3 months
Idebenone   effect of idebenone on cardiomyopathy in Friedreich's ataxia
Idebenone  Friedreich's ataxia and frataxin
Idebenone   Frataxin: Its role in iron metabolism and Friedreich's Ataxia
Idebenone   mitochondrial dysfunction in Friedreich's ataxia
Idebenone   helps heart function in Friedreich's ataxia

Idebenone  improves cerebral mitochondrial oxidative metabolism in MELAS
Idebenone  in young patients with mitochondrial encephalomyopathy (MELAS)
Idebenone  therapy in Mitochondrial encephalomyopathy (MELAS)
Idebenone  and Mitochondrial encephalomyopathy (MELAS)
Idebenone  successful therapy with idebenone in Mitochondrial encephalomyopathy (MELAS)
Idebenone  improvement in mitochondrial cardiomyopathy following treatment with idebenone

Idebenone   effect of idebenone on cardiomyopathy in Friedreich's ataxia

Leber hereditary optic neuropathy (LHON)
Idebenone  does it shorten the time to visual recovery in Leber hereditary optic neuropathy?
Idebenone  improvement in a patient with Leber's hereditary optic neuropathy (LHON)

Idebenone  use in age-related cognitive disorders

Idebenone  protects hippocampal neurons against beta amyloid neurotoxicity

functions as a potent protective hepatocyte antioxidant

neuroprotective effects of idebenone can be attributed to its antioxidant ability

inhibition of brain mitochondrial swelling

suppression of cold ischemia/reperfusion injury of liver endothelium

ability to eliminate a nitroxide radical in the rat

Idebenone  interaction with respiratory complexes of heart mitochondria

Idebenone  effect on serotonin release and seroton receptors in rats

Idebenone  protects hepatic microsomes against damage in organ preservation solutions

protects against toxicity induced by low density lipoprotein

Idebenone  protects against disorders due to cerebral hypoxia or ischemia

Idebenone  protects against toxicity induced by low density lipoprotein

Idebenone  attenuates neuronal degeneration induced by excitotoxins

Idebenone  augments long-term potentiation in hippocampal slices in the guinea pig

effects on lipid peroxidation in erythrocytes of stroke-prone, hypertensive rats

Idebenone  brain distribution and its effect on local cerebral glucose utilization in rats

Idebenone  effects on acetylcholine levels in the brains of rats with cerebral ischemia

Idebenone  protective effect of idebenone against hypoxia in mice

Idebenone  improves learning and memory impairment induced in rats

Idebenone  effects of idebenone on neurological deficits in stroke-prone rats

  effects on memory induced impairment in rats

Idebenone  effects of idebenone on cerebral blood flow in rats with cerebral ischemia

inhibition of brain mitochondrial swelling by idebenone

inhibition of platelet aggregation by idebenone

Idebenone  effects of idebenone on monoamine metabolites of patients with dementia

effects of idebenone on metabolism of monoamines and cyclic AMP formation in rats

  effects on impairment of radial maze learning in cerebral embolized rats

Idebenone  effect of idebenone on lipid peroxidation in rat brain homogenate

Idebenone  effects on muricidal behavior in rats with raphe lesions

Idebenone  inhibitory effect of idebenone on vascular lesions in hypertensive rats